Nedosiran sodium

• CAT Number: I041320
• CAS Number: 2247026-22-6
• Molecular Weight: 22183.60
• Purity: 98%
• Target: ASGPR;LDHA
• Target Protein: P00338
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.

Nedosiran sodium（Cat No.:I041320）is an RNA interference (RNAi) therapeutic designed to treat primary hyperoxaluria, a rare genetic disorder that leads to excessive oxalate production and kidney stone formation. Nedosiran targets the liver enzyme glycolate oxidase (GO), inhibiting its activity and reducing the production of oxalate, the compound responsible for kidney damage in hyperoxaluria patients. Administered via subcutaneous injection, it offers a novel, targeted approach to lowering oxalate levels, potentially preventing kidney failure. Nedosiran’s efficacy and safety profile make it a promising treatment for managing primary hyperoxaluria.

Reference

[1]. Kevin Shee, et al. Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report. Urology.2021 Oct;156:e147-e149.
[Content Brief]

[2]. Gema Ariceta, et al. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep. 2021 Feb 3;6(4):1088-1098.
[Content Brief]

[3]. Thomas A Forbes, et al. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol. 2021 May 22.
[Content Brief]